Deals, Development and Manufacturing

GSK and CureVac Enter into Licensing Agreement

July 04, 2024

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership

July 04, 2024

LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.

Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development

July 02, 2024

This collaboration aims to support and accelerate clinical development of advanced and novel technologies.

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

June 29, 2024

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

June 28, 2024

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.

CordenPharma and Certest Team Up on Ionizable Lipids to Develop LNP Formulations

June 12, 2024

CordenPharma has partnered with Spain-based Certest to develop ionizable lipids for LNP formulations.

CGT Catapult and CATTI Establish Shared Training Standards for Advanced Therapies

June 04, 2024

CGT Catapult and CATTI aim to standardize advanced therapy manufacturing with new aligned training standards.

CGT Catapult and Cellular Origins Team Up to Develop Automated CGT Manufacturing

June 01, 2024

CGT Catapult will implement Cellular Origins' robotic platform in its Stevenage, UK, site to establish automated CGT manufacturing.

Johnson & Johnson to Acquire Global Rights to Numab Therapeutics’ Bispecific Antibody for Atopic Dermatitis in $1.25 Billion Deal

May 30, 2024

Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.

AGC Biologics Partners with BioConnection to Offer Biopharma Drug Substance and Drug Product Development and Manufacturing

May 25, 2024

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.